Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Melanoma 39Uveal Melanoma 10Prostatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Adenoma, Islet Cell 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1Leukemia, Plasma Cell 1Leukemia 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Congenital Abnormalities 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Bile Duct Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 401Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 138Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × incomplete Freund's adjuvant × Clear all
NCT00079157 2020-02-05

Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
28 enrolled
Breast

Breast Neoplasms

NCT00640861 2018-10-31

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

Mayo Clinic

Phase EARLY_PHASE1 Completed
45 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡